Testing for human papillomavirus in cervical cancer screening

High‐risk human papillomavirus (hrHPV) testing has become an integral component of cervical cancer screening, given that persistent infection with hrHPV was recognized as a significant risk factor for most precancers and cancers of the cervix. Particularly, testing for hrHPV types (in conjunction with cervical cytology) has been approved for primary screening in women over 30 years of age and for cost‐effective triaging of equivocal cervical cytology results. HPV was a small double‐stranded DNA virus that cannot be cultured in vitro; so, different types of tests have been developed to detect its presence. Various molecular techniques were available for detecting the presence and/or quantity of hrHPV. In this review, the testing options for hrHPV and its surrogates, with an emphasis on those approved by the US Food and Drug Administration (FDA), were detailed. Cancer (Cancer Cytopathol) 2011;. © 2011 American Cancer Society.

[1]  E. Barr,et al.  Quadrivalent-human-papillomavirus-vaccine , 2007, Reactions Weekly.

[2]  I. Kristiansen,et al.  HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review. , 2011, Gynecologic oncology.

[3]  T. Wright,et al.  High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. , 2011, American journal of clinical pathology.

[4]  B. Patterson,et al.  Quantification of intracellular HPV E6/E7 mRNA expression increases the specificity and positive predictive value of cervical cancer screening compared to HPV DNA. , 2011, Gynecologic oncology.

[5]  P. Ghatage,et al.  Aptima HPV E6/E7 mRNA Test Is as Sensitive as Hybrid Capture 2 Assay but More Specific at Detecting Cervical Precancer and Cancer , 2010, Journal of Clinical Microbiology.

[6]  M. von Knebel Doeberitz,et al.  Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results. , 2010, Gynecologic oncology.

[7]  M. Stoler,et al.  Using Biomarkers as Objective Standards in the Diagnosis of Cervical Biopsies , 2010, The American journal of surgical pathology.

[8]  Y. Liu,et al.  Human Papillomavirus Messenger RNA Assay for Cervical Cancer Screening: The Shenzhen Cervical Cancer Screening Trial I , 2010, International Journal of Gynecologic Cancer.

[9]  C. Bergeron,et al.  The sensitivity and specificity of p16(INK4a) cytology vs HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL pap cytology results. , 2010, American journal of clinical pathology.

[10]  Kayo Miyazaki,et al.  Comparison of methods trial for high‐risk HPV , 2009, Diagnostic cytopathology.

[11]  M. Guo,et al.  Hybrid capture 2 human papillomavirus DNA testing for women with atypical squamous cells of undetermined significance papanicolaou results in SurePath and ThinPrep specimens , 2009, Cancer.

[12]  Yong Dai,et al.  Gain of the Human Telomerase RNA Gene TERC at 3q26 is Strongly Associated With Cervical Intraepithelial Neoplasia and Carcinoma , 2009, International Journal of Gynecologic Cancer.

[13]  C. Giachetti,et al.  Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[14]  C. R. Starkey,et al.  The clinical performance of Invader technology and SurePath when detecting the presence of high-risk HPV cervical infection. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[15]  J. T. Cox,et al.  Commentary on: Statement on HPV DNA test utilization , 2009, Diagnostic cytopathology.

[16]  A. Seppo,et al.  Gain of 3q26: a genetic marker in low-grade squamous intraepithelial lesions (LSIL) of the uterine cervix. , 2009, Gynecologic oncology.

[17]  J. Dillner,et al.  Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. , 2009, Journal of the National Cancer Institute.

[18]  Feng Chen,et al.  A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. , 2008, The Lancet. Oncology.

[19]  Lawrence R. Johnson,et al.  A comparison of two methods to determine the presence of high-risk HPV cervical infections. , 2008, American journal of clinical pathology.

[20]  F. Ng,et al.  Cytological distinction between high-risk and low-risk human papillomavirus infections in SurePath liquid-based cell preparations , 2008, Journal of Clinical Pathology.

[21]  C. Ginocchio,et al.  Comparison of the Third Wave Invader Human Papillomavirus (HPV) Assay and the Digene HPV Hybrid Capture 2 Assay for Detection of High-Risk HPV DNA , 2008, Journal of Clinical Microbiology.

[22]  D. Wilbur,et al.  A peer comparison program for the quality assurance of human papillomavirus DNA detection using the Digene Hybrid Capture II/SurePath method shows excellent analytic interlaboratory correlation , 2007, Cancer.

[23]  J. Dillner,et al.  Human Papillomavirus and Papanicolaou Tests to Screen for Cervical Cancer , 2008 .

[24]  Diane Solomon,et al.  2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. , 2007, American journal of obstetrics and gynecology.

[25]  H. Lawson,et al.  Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2007, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[26]  M. Schiffman,et al.  The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. , 2007, American journal of clinical pathology.

[27]  M. Troxell,et al.  p16INK4A Immunohistochemistry is Superior to HPV In Situ Hybridization for the Detection of High-risk HPV in Atypical Squamous Metaplasia , 2007, The American journal of surgical pathology.

[28]  C. Woodman,et al.  The natural history of cervical HPV infection: unresolved issues , 2007, Nature Reviews Cancer.

[29]  J. Dillner,et al.  Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. , 2006, Vaccine.

[30]  M. Poljak,et al.  Resolving repeatedly borderline results of Hybrid Capture 2 HPV DNA Test using polymerase chain reaction and genotyping. , 2006, Journal of virological methods.

[31]  M. Stanley.  Immune responses to human papillomavirus. , 2006, Vaccine.

[32]  B. King,et al.  p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer , 2005, Journal of Clinical Pathology.

[33]  C. Dalrymple,et al.  p16INK4a as a complementary marker of high‐grade intraepithelial lesions of the uterine cervix. I: Experience with squamous lesions in 189 consecutive cervical biopsies , 2005, Pathology.

[34]  D. Malinowski.  Molecular diagnostic assays for cervical neoplasia: emerging markers for the detection of high-grade cervical disease. , 2005, BioTechniques.

[35]  E. van Marck,et al.  P16INK4a as an adjunct marker in liquid‐based cervical cytology , 2004, International journal of cancer.

[36]  M. Ziol,et al.  Efficiency of the Hybrid Capture 2 HPV DNA Test in Cervical Cancer Screening , 2003 .

[37]  M. Ziol,et al.  Efficiency of the hybrid capture 2 HPV DNA test in cervical cancer screening. A study by the French Society of Clinical Cytology. , 2003, American journal of clinical pathology.

[38]  N. Kiviat,et al.  p16INK4a Expression Correlates with Degree of Cervical Neoplasia: A Comparison with Ki-67 Expression and Detection of High-Risk HPV Types , 2003, Modern Pathology.

[39]  M. Bibbo,et al.  P16INK4A as an adjunct test in liquid-based cytology. , 2003, Analytical and quantitative cytology and histology.

[40]  Eileen M. Burd,et al.  Human Papillomavirus and Cervical Cancer , 1988, The Lancet.

[41]  W. Peters,et al.  Cervical cytology screening , 1988, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[42]  M. Poljak,et al.  Hybrid Capture II HPV Test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. , 2002, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[43]  Attila Lorincz,et al.  Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[44]  Thomas C Wright,et al.  Consensus Guidelines for the Management of Women With Cervical Cytological Abnormalities , 2002 .

[45]  M. Schiffman,et al.  Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. , 2001, Journal of the National Cancer Institute.

[46]  Harald zur Hausen,et al.  Papillomaviruses Causing Cancer: Evasion From Host-Cell Control in Early Events in Carcinogenesis , 2000 .

[47]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[48]  M. Schiffman.  New epidemiology of human papillomavirus infection and cervical neoplasia. , 1995, Journal of the National Cancer Institute.

[49]  V. Moreno,et al.  Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective , 1995 .

[50]  V. Moreno,et al.  Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. , 1995, Journal of the National Cancer Institute.

[51]  S Wacholder,et al.  Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. , 1993, Journal of the National Cancer Institute.

[52]  K. Holmes,et al.  A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection , 1992, The New England journal of medicine.

[53]  Steven Wolinsky,et al.  Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. , 1992, Human pathology.